Stada Grows In Russia And CIS With Takeda Deal
Stada To Pay $660m For 20 OTC And Prescription Brands
Stada will pay $660m for a basket of 20 brands from Takeda to expand its consumer health portfolio in Russia and a number of strategically important CIS markets.
You may also be interested in...
Stada has struck a deal to acquire the prescription and consumer health businesses of Ukraine’s Biopharma, including local manufacturing operations and around 300 new staff. Biopharma will retain its blood plasma-based business.